Addressing analytical control challenges for different plasmid DNA products

Since the outbreaks of COVID-19, DNA vaccines are promising in the SARS-CoV-2 vaccine race although they have a new platform technology that was not previously available on the market for human use.

Since the approval of the product Luxtura® using AAV as a vector in 2017, more and more clinical trials have been carried out rapidly, and various early clinical trial projects for rare diseases and a wide range of indications ..

CGT has made a great breakthrough in the recent years, however the industry is facing challenges in developing stable and scalable manufacturing process for viral vectors.

As more CGT products are in clinical phases, demand for large-scale lentiviral vector manufacturing and implementation of suspension system are increasing. GenScript ProBio is dedicated to improving technologies and product quality to me